|
Over all
|
0
|
18
|
13
|
11
|
42.9 (27.7–59.0)
|
73.8 (58.0–86.2)
|
|
BDca
|
0
|
11
|
10
|
6
|
40.7 (22.4–61.2)
|
77.8 (57.8–91.4)
|
|
GBca
|
0
|
7
|
3
|
5
|
46.7 (21.1–73.5)
|
66.7 (38.4–88.2)
|
|
Primary or local recurrence
|
| |
CR
|
PR
|
NC
|
PD
|
Response Rate (%)95%C.I. CR+PR/TOTAL
|
Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
|
|
Over all
|
0
|
14
|
8
|
6
|
50.0 (30.6–69.4)
|
78.6 (59.0–91.7)
|
|
BDca
|
0
|
9
|
6
|
3
|
50.0 (26.0–74.0)
|
83.3 (58.6–96.5)
|
|
GBca
|
0
|
5
|
2
|
3
|
50.0 (18.6–81.4)
|
70.0 (34.7–93.5)
|
|
Metastatic lesion
|
| |
CR
|
PR
|
NC
|
PD
|
Response Rate (%)95%C.I. CR+PR/TOTAL
|
Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
|
|
Over all
|
0
|
10
|
12
|
9
|
32.3 (16.7–51.4)
|
71.0 (52.0–85.8)
|
|
BDca
|
0
|
6
|
9
|
5
|
30.0 (11.8–54.3)
|
75.0 (50.9–91.4)
|
|
GBca
|
0
|
4
|
3
|
4
|
36.4 (10.8–69.3)
|
66.7 (30.7–89.2)
|
